NASDAQ:PEAR Pear Therapeutics (PEAR) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free PEAR Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume7.75 million shsMarket Capitalization$4.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Pear Therapeutics alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Pear Therapeutics Stock (NASDAQ:PEAR)Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.Read More Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" PEAR Stock News HeadlinesApril 18, 2024 | yahoo.comWork on Highway 99 northbound lanes near Avenue 12 beginsApril 9, 2024 | msn.comExclusive: AlleyCorp raises a $250 million fund, taking on external investors for the first timeApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 5, 2024 | msn.comFDA approves first prescription-only app for depressionApril 1, 2024 | finance.yahoo.comAcorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase AgreementApril 1, 2024 | wsj.comAcorda Therapeutics Files for Bankruptcy ProtectionMarch 28, 2024 | forbes.comVirtual Clinic Pelago Is Reimagining Rehab With $58 Million In New FundingMarch 19, 2024 | bizjournals.comGirl's rare disease inspired new drug model. Now the drug trial has hit a pivotal pointApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 15, 2024 | finance.yahoo.comBetter Therapeutics lays off staff, considers winding down businessMarch 14, 2024 | finance.yahoo.comBratu named marketing and development director for State GamesFebruary 21, 2024 | finance.yahoo.comBetter Therapeutics wins breakthrough status for health app to treat liver diseaseJanuary 31, 2024 | finance.yahoo.comGlobal Internet Addiction Disorder Market Size Is Expected To Hold a Significant Share By 2033 | CAGR of 11.45%January 31, 2024 | finance.yahoo.comSmart Pills Market Set to Soar Past USD 12.39 billion by 2030January 31, 2024 | forbes.comHow Pharma Can Borrow A Page From Digital Health Investors’ PlaybookJanuary 31, 2024 | axios.comCognito Therapeutics raises $35M for neuro deviceJanuary 26, 2024 | finance.yahoo.comHealthcare bankruptcies reached five-year peak in 2023, report findsJanuary 11, 2024 | finance.yahoo.comAcorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025December 20, 2023 | finance.yahoo.comDigital Therapeutics Global Market to Observe Stunning Growth at a CAGR of ~28% by 2028 | DelveInsightNovember 11, 2023 | morningstar.comPear Therapeutics Inc Class A PEARQNovember 9, 2023 | finance.yahoo.comNox Health Appoints Frances Thorndike, Ph.D. to lead Medical & Scientific AffairsOctober 27, 2023 | seekingalpha.comPEARQ Pear Therapeutics, Inc.October 24, 2023 | benzinga.comDigital Therapeutics Market Is Projected to Gain $22.60 Billion By 2031, Growing at a 19.4% CAGR: Allied Market ResearchOctober 18, 2023 | bizjournals.comDeals of the Year: Somryst 'literally completes our portfolio,' Nox Health CEO saysOctober 10, 2023 | bizjournals.comBiotech's 2023 ghosts haunt efforts to exorcise downturnSeptember 28, 2023 | benzinga.comMigraine Pipeline, Clinical Trials, Emerging Therapies and FDA Approvals 2023 (Updated)September 25, 2023 | finance.yahoo.comPear Therapeutics, Inc. (PEARQ)See More Headlines Receive PEAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pear Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryN/A Current SymbolNASDAQ:PEAR CUSIPN/A CIK1835567 Webpeartherapeutics.com Phone617-925-7848FaxN/AEmployees300Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,490,000.00 Net Margins-594.70% Pretax Margin-594.70% Return on Equity-217.85% Return on Assets-95.20% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.48 Sales & Book Value Annual Sales$12.69 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / BookN/AMiscellaneous Outstanding Shares142,739,000Free Float98,918,000Market Cap$4.17 million OptionableNot Optionable Beta0.45 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Corey M. McCann M.D. (Age 43)Ph.D., Founder, Pres, CEO & Director Comp: $702.45kMr. Christopher D. T. Guiffre J.D. (Age 55)M.B.A., MBA, CFO, COO, Treasurer & Assistant Sec. Comp: $564.37kMs. Julia M. Strandberg M.B.A. (Age 48)Chief Commercial Officer Comp: $582.43kMr. Ronan P. O'Brien J.D. (Age 50)Chief Compliance Officer, Gen. Counsel & Sec. Ms. Meara MurphySr. Director of Corp. CommunicationsDr. Yuri Maricich M.B.A. (Age 43)M.D., Chief Medical Officer & Head of Devel. Mr. Chris Valosky M.B.A.VP of SalesMs. Katherine Jeffery M.Sc. (Age 56)Chief People Officer Ms. Erin K. Brenner (Age 50)Chief Product Devel. Officer Ms. Ellen E. Snow CPA (Age 50)CGMA, VP & Corp. Controller More ExecutivesKey CompetitorsUpHealthNYSE:UPHLEnsysce BiosciencesNASDAQ:ENSCSoligenixNASDAQ:SNGXTRACON PharmaceuticalsNASDAQ:TCONArtelo BiosciencesNASDAQ:ARTLView All Competitors PEAR Stock Analysis - Frequently Asked Questions How do I buy shares of Pear Therapeutics? Shares of PEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PEAR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersKeep Your Eyes on This Power-Mad PoliticianAltimetryThe Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pear Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
